Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to considerable advances in treatment, the rate of relapse remains high (ASCO, 2021; Samra et al, 2020). One reason for this is that older patients are often unable to tolerate curative therapy, leading to a lack of effective therapeutic options and less-than-optimal outcomes (Aldoss et al, 2019). In addition, variables such as comorbidities and cytogenic disease features make the selection of appropriate treatment difficult. Therefore, it is essential that the multidisciplinary team have a comprehensive understanding of emerging efficacy and safety data regarding novel therapeutic strategies. In this activity, Amir Fathi, MD, will update clinicians on strategies for developing individualized management plans in order to maximize treatment tolerability and improve outcomes for their patients with ALL.